Ensure your drug, device or diagnostic product gets reimbursed

To support health technology assessment, Numerus combines rigorous statistical principles with the methods of health economics in a unified regulatory approach that successfully supports the reimbursement of drugs, medical devices and diagnostics.

Our team are internationally located, provide multi-lingual support and have a solid understanding of country-specific guidelines.

Numerus integrates analyses, aimed at generating evidence for reimbursement, into early phase clinical study design. We also ensure broad forethought into how best to address available HTA guidance.

Numerus delivers all the appropriate modelling and analyses.